MediPharm Labs (TSE:LABS) has released an update.
MediPharm Labs Corp. has shown a robust financial performance in Q2 2024, with a significant improvement in adjusted EBITDA and a gross profit increase driven by enhanced operational efficiencies and international sales growth. The company is on the cusp of achieving profitability, marking the highest revenue and adjusted EBITDA in over three years, and maintains a strong cash position with minimal debt.
For further insights into TSE:LABS stock, check out TipRanks’ Stock Analysis page.
